Fingolimod-induced bladder lymphoma in a patient with multiple sclerosis

Saeed Vaheb; Elham Moases Ghaffary; Vahid Shaygannejad; Omid Mirmosayyeb

doi:10.1002/ccr3.7280

Fingolimod-induced bladder lymphoma in a patient with multiple sclerosis

Clin Case Rep. 2023 Apr 24;11(4):e7280. doi: 10.1002/ccr3.7280. eCollection 2023 Apr.

Authors

Saeed Vaheb¹, Elham Moases Ghaffary¹, Vahid Shaygannejad^{1

2}, Omid Mirmosayyeb^{1

2}

Affiliations

¹ Isfahan Neurosciences Research Center Isfahan University of Medical Sciences Isfahan Iran.
² Department of Neurology, School of Medicine Isfahan University of Medical Sciences Isfahan Iran.

Abstract

Key clinical message: Malignancies were reported in some studies following taking Fingolimod. We reported a case of bladder lymphoma after taking Fingolimod. Physicians should consider the carcinogenic effects of Fingolimod in long-term use and replace it with safer medicines.

Abstract: Fingolimod is a medication with a potential cure to control multiple sclerosis (MS) relapses. Here we describe a 32-year-old woman with relapsing-remitting multiple sclerosis who developed bladder lymphoma induced by long-term use of Fingolimod. Physicians should consider the carcinogenic effects of Fingolimod in long-term use and replace it with safer medicines.

Keywords: Fingolimod; bladder lymphoma; multiple sclerosis.

Publication types

Case Reports